Tagged with R

Hong Kong In 2017, Hong Kong fended off perennial competitors, life sciences hubs and innovation powerhouses, Switzerland and Singapore, to rank first in the International Institute for Management Development (IMD)’s World Competitiveness Rankings, clear evidence that conditions are ripe in Hong Kong to develop the first biotech unicorn – a start-up company…

Ukraine Victoria Bandyk, chief operating officer of the Bioscience Group, provides insights into the unique added value and the international development of this comprehensive group of companies, which aims to support local and international companies in positioning, registering, and promoting medicines across targeted European and Asian markets, finding strategic partners across…

Austria Ana Kostova, Austrian country president for AstraZeneca, a global powerhouse in innovative drugs and R&D, discusses the opportunities and challenges of introducing innovative treatments into the Austrian healthcare system as well as AstraZeneca´s exciting pipeline, especially in the field of oncology. She also provides an insight into the future potential…

Hong Kong Johnny Tse, general manager of Roche Diagnostics Hong Kong, talks about the past seven years managing the affiliate, how the company became a market leader, and his aim to position Roche Diagnostic as a solutions provider. Having managed Roche Diagnostics Hong Kong for nearly seven years now, what have been…

Singapore Claus Zieler discusses the Asia Pacific region’s importance to Bayer’s global operations, the company’s commitment to increasing its portfolio of innovative medicines, and the potential for innovation coming from Asian markets. Having spent four years in Japan previously, how have you had to adapt to serving the entire Asia Pacific…

Iceland Jakob Falur Gardarsson, general manager at Frumtök, the Icelandic Association of the Pharmaceutical Industry, highlights access as the main challenge that needs to be met in order to propel Iceland’s healthcare system to the level of other Northern European countries. He also expresses his trust in the willingness of the…

Hong Kong Described as the first unicorn [a startup company valued at over USD 1 billion] of Hong Kong, Cirina has recently merged with Grail to further improve detection of cancer at its early stage. Pharmaboardroom sat down with Professor Denis Lo, the man behind Cirina’s technology, to further discuss his groundbreaking…

Ukraine Roman Gladkyi, general manager of Ferring Ukraine, describes the current opportunities and areas for improvement he identifies within Ukraine’s pharmaceutical market and the country’s evolving heath system, with a special focus on Ferring’s key areas of expertise such as reproductive health and obstetric products. You have been heading Ferring Ukraine…

Hong Kong Charles Ng and Simon Tsang of InvestHK, Hong Kong’s investment promotion agency, discuss the territory’s strengths in the life sciences sector, the potential of the HK industry to grow further, and its regional significance. The Swiss-based International Institute for Management Development (IMD) recently placed Hong Kong at the top of…

Austria Dr. Christoph Zielinski, head of the organizational unit of the Comprehensive Cancer Center of Vienna (CCC), a representative of the Austrian oncological community, provides an insight into the key activities of the center. He also gives an overview of the current state of the Austrian healthcare and oncology ecosystem as…

Hong Kong Scott Curley, general manager of Astra Zeneca Hong Kong, discusses how his affiliate managed to achieve its successful product launch track record; shares his insights on the key specificities of Hong Kong and further explains why it is an important market for Astra Zeneca’s global R&D. Having previously worked extensively…

Indonesia Marlia Hayati and Joey Romana, President Director and Vice President Director at PT Darya-Varia Laboratoria, share insights about the company’s strong brand equity and pioneering manufacturing strategy. In 2016, the sales growth rate achieved by Darya-Varia Laboratoria was 11 percent, above market average. What business approach is the secret to…